Marc Matrana, MD
Hematology & Oncology · New Orleans, LANPI 1598958316
Payments from drug & device makers
Across 1,196 payments — averaging $3855.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.5M
- Eisai Inc.$352K
- Pfizer$285K
- AstraZeneca$196K
- E.r. Squibb & Sons, L.L.C.$151K
- Incyte Corporation$137K
- plus $961K from 34 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 221 | $2,530,670 |
| Eisai Inc. | 200 | $351,558 |
| Pfizer | 34 | $285,448 |
| AstraZeneca | 134 | $195,721 |
| E.r. Squibb & Sons, L.L.C. | 79 | $151,110 |
| Incyte Corporation | 99 | $136,552 |
| Eli Lilly | 7 | $116,255 |
| Exelixis Inc. | 55 | $96,702 |
| AbbVie | 12 | $96,170 |
| Seagen Inc. | 37 | $91,614 |
| Genentech, Inc. | 8 | $76,530 |
| Puma Biotechnology, Inc. | 13 | $72,424 |
| Astellas Pharma US Inc | 42 | $63,192 |
| Johnson & Johnson | 58 | $54,704 |
| Clovis Oncology, Inc. | 19 | $54,579 |
| EMD Serono, Inc. | 34 | $47,537 |
| Novocure Inc. | 34 | $47,098 |
| Bayer | 28 | $30,857 |
| Astellas Pharma Global Development | 5 | $25,905 |
| Helsinn Healthcare SA | 3 | $22,500 |
| Blueprint Medicines Corporation | 1 | $14,000 |
| Genentech USA, Inc. | 9 | $11,281 |
| Daiichi Sankyo Inc. | 14 | $10,847 |
| Sanofi | 4 | $6,154 |
| Sirtex Medical Inc | 13 | $6,075 |
| Novartis | 5 | $3,670 |
| Amgen | 2 | $3,665 |
| F. Hoffmann-la Roche AG | 3 | $3,326 |
| Immunomedics, Inc. | 1 | $2,475 |
| Pharmaand GmbH | 1 | $1,000 |
| Halozyme Inc | 1 | $877 |
| Tempus AI, Inc | 9 | $551 |
| Sanofi-aventis U.S. LLC | 2 | $175 |
| Novocure GmbH | 1 | $139 |
| AVEO Pharmaceuticals, Inc. | 1 | $91 |
| Bristol Myers Squibb | 2 | $72 |
| Beigene USA, Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $32 |
| Gilead | 1 | $20 |
| Myovant Sciences Inc. | 1 | $17 |
How this compares
$4,611,626 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$4.2M
- Carter DavisNew Orleans$1.6M
- Maissaa JanbainNew Orleans$1.5M
- Lingling duNew Orleans$1.2M
- John ColeNew Orleans$896K
- Cindy LeissingerNew Orleans$432K
- Furhan YunusNew Orleans$422K
- David MorrisonNew Orleans$313K
- Stefan GrantNew Orleans$261K
- Michelle LochNew Orleans$232K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.